D5Pharma’s groundbreaking new cancer vaccine, MetVax, capitalizes on a precisely defined protein fragment of carcinoembryonic antigen—a well-established mediator of adhesion and tumor implantation— to block metastasis.
D5Pharma’s groundbreaking new cancer vaccine, MetVax, capitalizes on a precisely defined protein fragment of carcinoembryonic antigen—a well-established mediator of adhesion and tumor implantation— to block metastasis.